Cardiovascular effects of xylazine recorded with telemetry in the dog

• Published in: Journal of veterinary medicine. Series A 2003-12, Vol.50 (10), p.479-483
• Main Authors: Ilbäck, N.-G., Stålhandske, T.
• Format: Article
• Language: English
• Subjects: Adrenergic alpha-Agonists - administration & dosage; Adrenergic alpha-Agonists - pharmacology; Animals; Blood Pressure - drug effects; Dogs - physiology; Female; Heart Rate - drug effects; Injections, Intramuscular; Telemetry - veterinary; Xylazine - administration & dosage; Xylazine - pharmacology
• ISSN: 0931-184X; 1439-0442
• DOI: 10.1111/j.1439-0442.2004.00585.x

Summary Cardiovascular effects of xylazine have not been studied with telemetry in dogs. In the present study, the effects on cardiovascular parameters after intramuscular (i.m.) administration of 2.0 mg/kg xylazine were studied via telemetry in unrestrained dogs. Telemetry transmitters were implanted subcutaneously (s.c.) with a pressure catheter in the femoral artery. Cardiovascular effects and body temperature effects were assessed after i.m. administration of xylazine. Heart rate decreased for about 10 min and was continuously depressed during 60 min. Thereafter, heart rate slowly increased but had not fully reached pre‐dose values 4 h after treatment. Both systolic and diastolic blood pressure increased immediately after administration of xylazine. The systolic blood pressure showed a peak increase for about 5–10 min and then decreased below the baseline value not normalizing within 90 min. The diastolic blood pressure peaked 5–10 min after xylazine administration but did not return to baseline level until 50 min after administration. Body temperature decreased continuously for about 90 min and remained low for more than 4 h after treatment. An additional administration of xylazine to the same individuals after a recovery period of 4 weeks induced exactly the same response in systolic and diastolic blood pressure and in heart rate. By using the telemetric recording system it was possible to continuously evaluate xylazine‐induced cardiovascular responses in a way that is not possible with conventional techniques.